| | 242138-07-4 Basic information More.. |
| Product Name: | Omalizumab | | Synonyms: | OMALIZUMAB;Omalizumab - buffer solution;Immunoglobulin G1,anti-(human immunoglobulin E Fc region) (human-mouse monoclonal E25 clonepSVIE25 g-chain), disulfide withhuman-mouse monoclonal E25 clone pSVIE25 k-chain, dimer (9CI);Xolair;Research Grade Omalizumab(DHJ92701);humanized,asthma,IgE,CD40,allergic,IL-4,IL-6,FcγRIIb,Olizumab,Inhibitor,immunoglobulin,FcεRI,rhuMab-E25,Omalizumab,inhibit;Omalizumab (anti-IgE) | | CAS: | 242138-07-4 | | MF: | | | MW: | 0 | | EINECS: | | | Mol File: | Mol File |  |
Use
Omalizumab is a recombinant humanized construct of murine IgG1k monoclonal antibody introduced for the treatment of allergic asthma. It forms complexes with free, circulating serum IgE, which results in the inhibition of binding of IgE to the high-affinity IgE-receptor (FCeRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response.
- Omalizumab
-
- US $0.00-0.00 / mg
- 2021-09-16
- CAS:242138-07-4
- Min. Order: 10mg
- Purity: 99%
- Supply Ability: 100KG
|
|
242138-07-4
Recommend Suppliers |
|